Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis

Supplemental Digital Content is available in the text. Background: Trimethylamine N-oxide (TMAO)—a gut-derived metabolite—is elevated in heart failure (HF) and linked to poor prognosis. We investigated variations in TMAO in HF, left ventricular assist device (LVAD), and heart transplant (HT) and assessed its relation with inflammation, endotoxemia, oxidative stress, and gut dysbiosis. Methods: We enrolled 341 patients. TMAO, CRP (C-reactive protein), IL (interleukin)-6, TNF-α (tumor necrosis factor alpha), ET-1 (endothelin-1), adiponectin, lipopolysaccharide, soluble CD14, and isoprostane were measured in 611 blood samples in HF (New York Heart Association class I–IV) and at multiple time points post-LVAD and post-HT. Gut microbiota were assessed via 16S rRNA sequencing among 327 stool samples. Multivariable regression models were used to assess the relationship between TMAO and (1) New York Heart Association class; (2) pre- versus post-LVAD or post-HT; (3) biomarkers of inflammation, endotoxemia, oxidative stress, and microbial diversity. Results: ln-TMAO was lower among HF New York Heart Association class I (1.23 [95% CI, 0.52–1.94] µM) versus either class II, III, or IV (1.99 [95% CI, 1.68–2.30], 1.97 [95% CI, 1.71–2.24], and 2.09 [95% CI, 1.83–2.34] µM, respectively; all P<0.05). In comparison to class II–IV, ln-TMAO was lower 1 month post-LVAD (1.58 [95% CI, 1.32–1.83] µM) and 1 week and 1 month post-HT (0.97 [95% CI, 0.60–1.35] and 1.36 [95% CI, 1.01–1.70] µM). ln-TMAO levels in long-term LVAD (>6 months: 1.99 [95% CI, 1.76–2.22] µM) and HT (>6 months: 1.86 [95% CI, 1.66–2.05] µM) were not different from symptomatic HF. After multivariable adjustments, TMAO was not associated with biomarkers of inflammation, endotoxemia, oxidative stress, or microbial diversity. Conclusions: TMAO levels are increased in symptomatic HF patients and remain elevated long term after LVAD and HT. TMAO levels were independent from measures of inflammation, endotoxemia, oxidative stress, and gut dysbiosis.

[1]  S. Hazen,et al.  Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[2]  R. Nandakumar,et al.  Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  R. Nandakumar,et al.  Plasma Trimethylamine-N-oxide and impaired glucose regulation: Results from The Oral Infections, Glucose Intolerance and Insulin Resistance Study (ORIGINS) , 2020, PloS one.

[4]  A. Masoumi,et al.  Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes Among Patients With a Left Ventricular Assist Device , 2020, Circulation. Heart failure.

[5]  D. Jacobs,et al.  Association Between Nitrate‐Reducing Oral Bacteria and Cardiometabolic Outcomes: Results From ORIGINS , 2019, Journal of the American Heart Association.

[6]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[7]  J. Ferguson,et al.  The Gut Microbiome and Response to Cardiovascular Drugs. , 2019, Circulation. Genomic and precision medicine.

[8]  G. Dellgren,et al.  The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  Li Song,et al.  Plasma Trimethylamine N-Oxide as a Novel Biomarker for Plaque Rupture in Patients With ST-Segment–Elevation Myocardial Infarction , 2019, Circulation. Cardiovascular interventions.

[10]  Donald J L Jones,et al.  Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure: results from BIOSTAT‐CHF , 2018, European journal of heart failure.

[11]  Paul Theodor Pyl,et al.  Recovery of gut microbiota of healthy adults following antibiotic exposure , 2018, Nature Microbiology.

[12]  Michael R. Taylor,et al.  An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  S. Hazen,et al.  Gut Microbiota–Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[14]  T. Ueland,et al.  Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent Cohorts. , 2018, Journal of the American College of Cardiology.

[15]  M. Kahn,et al.  Reporting Data Quality Assessment Results: Identifying Individual and Organizational Barriers and Solutions , 2017, EGEMS.

[16]  M. Bell,et al.  Superiority of Serum Cystatin C Over Creatinine in Prediction of Long-Term Prognosis at Discharge From ICU , 2017, Critical care medicine.

[17]  Patrick B. Ryan,et al.  A Comparison of Data Quality Assessment Checks in Six Data Sharing Networks , 2017, EGEMS.

[18]  D. Pieper,et al.  Uncovering the trimethylamine-producing bacteria of the human gut microbiota , 2017, Microbiome.

[19]  W. Lieb,et al.  Heart failure is associated with depletion of core intestinal microbiota , 2017, ESC heart failure.

[20]  L. Räber,et al.  Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors , 2017, European heart journal.

[21]  Y. Naka,et al.  Changes in End-Organ Function in Patients With Prolonged Continuous-Flow Left Ventricular Assist Device Support. , 2017, The Annals of thoracic surgery.

[22]  Brian J. Bennett,et al.  Microbiota‐Dependent Metabolite Trimethylamine N‐Oxide and Coronary Artery Calcium in the Coronary Artery Risk Development in Young Adults Study (CARDIA) , 2016, Journal of the American Heart Association.

[23]  Stanley L. Hazen,et al.  Plasma Trimethylamine N-Oxide, a Gut Microbe-Generated Phosphatidylcholine Metabolite, Is Associated With Atherosclerotic Burden. , 2016, Journal of the American College of Cardiology.

[24]  P. Stenvinkel,et al.  Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease , 2016, PloS one.

[25]  S. Bhushan,et al.  Choline Diet and Its Gut Microbe–Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload–Induced Heart Failure , 2016, Circulation. Heart failure.

[26]  T. Karlsen,et al.  Microbiota‐dependent metabolite trimethylamine‐N‐oxide is associated with disease severity and survival of patients with chronic heart failure , 2015, Journal of internal medicine.

[27]  Zeneng Wang,et al.  Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. , 2015, Journal of cardiac failure.

[28]  S. Hazen,et al.  Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease , 2015, Circulation research.

[29]  S. Hazen,et al.  Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. , 2014, Journal of the American College of Cardiology.

[30]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[31]  S. Hazen,et al.  Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. , 2014, European heart journal.

[32]  S. Kimmel,et al.  Prevalence and Prognostic Importance of Changes in Renal Function After Mechanical Circulatory Support , 2014, Circulation. Heart failure.

[33]  I. Piña,et al.  Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.

[34]  S. Hazen,et al.  Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. , 2013, The New England journal of medicine.

[35]  K. Hatori,et al.  Trimethylamine N-oxide suppresses the activity of the actomyosin motor. , 2012, Biochimica et biophysica acta.

[36]  S. Hazen,et al.  Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events , 2012, Circulation. Heart failure.

[37]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[38]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[39]  G. Beck,et al.  Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. , 2011, Kidney international.

[40]  D. Relman,et al.  Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation , 2010, Proceedings of the National Academy of Sciences.

[41]  M. Crespo-Leiro,et al.  Prevalence and severity of renal dysfunction among 1062 heart transplant patients according to criteria based on serum creatinine and estimated glomerular filtration rate: results from the CAPRI study , 2010, Clinical transplantation.

[42]  Jeroen J. Bax,et al.  Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. , 2009, European heart journal.

[43]  P. Poole‐Wilson,et al.  Altered intestinal function in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[44]  R. Milne,et al.  Oral L-carnitine: metabolite formation and hemodialysis. , 2006, Current drug metabolism.

[45]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[46]  M. Nieminen,et al.  Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. , 2006, European heart journal.

[47]  T. Sauerbruch,et al.  Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  Christine A. White,et al.  Estimating glomerular filtration rate in kidney transplantation: a comparison between serum creatinine and cystatin C-based methods. , 2005, Journal of the American Society of Nephrology : JASN.

[49]  B. Psaty,et al.  Cystatin-C and mortality in elderly persons with heart failure. , 2005, Journal of the American College of Cardiology.

[50]  F. Waagstein,et al.  Predictors and evolution of renal function during 9 years following heart transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[51]  P J Sadler,et al.  Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. , 1991, Biochimica et biophysica acta.

[52]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[53]  R. Califf,et al.  Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. , 2015, JACC. Heart failure.